Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities

G. Bacci, S. Ferrari, L. Sangiorgi, P. Picci, R. Casadei, M. Orlandi, D. Iantorno, A. Battistini, A. Zanone

Research output: Contribution to journalArticle

Abstract

Six hundred and fifty-six patients with osteosarcoma of the extremities (107 metastatic and 549 with localized disease) were followed from 2.5 to 20 years (average: 10 years) to evaluate whether their pretreatment serum lactate dehydrogenase (LDH) enzyme levels had a clinical value in predicting the course of the disease. The percentage of patients who had an elevated serum LDH at the time of diagnosis was significantly higher in those patients with metastatic disease than those who had localized disease (64% versus 33%, p <0.0001). For those who presented with localized disease and had an increased serum LDH level, far more ultimately developed a relapse of disease (60% versus 38%, p <0.0001) than those patients with a normal pre-treatment value. The prognostic significance of the serum LDH was more pronounced for the 247 patients treated with adjuvant chemotherapy (relapse rate of 72% versus 48%: p <0.0002) than the 271 patients treated with neoadjuvant chemotherapy (relapse rate: 46% versus 28%, p <0.005). Following treatment, serum LDH levels almost uniformly returned to normal and no correlation between postoperative levels and relapse of disease could be identified. We have demonstrated that in patients with osteosarcoma of the extremities, pretreatment serum LDH levels have a definite prognostic value which should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.

Original languageEnglish
Pages (from-to)204-210
Number of pages7
JournalJournal of Chemotherapy
Volume6
Issue number3
Publication statusPublished - 1994

Fingerprint

Osteosarcoma
L-Lactate Dehydrogenase
Extremities
Serum
Recurrence
Adjuvant Chemotherapy
Therapeutics
Randomized Controlled Trials
Drug Therapy
Enzymes

Keywords

  • lactate dehydrogenase
  • osteosarcoma
  • serum LDH

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)

Cite this

Bacci, G., Ferrari, S., Sangiorgi, L., Picci, P., Casadei, R., Orlandi, M., ... Zanone, A. (1994). Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. Journal of Chemotherapy, 6(3), 204-210.

Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. / Bacci, G.; Ferrari, S.; Sangiorgi, L.; Picci, P.; Casadei, R.; Orlandi, M.; Iantorno, D.; Battistini, A.; Zanone, A.

In: Journal of Chemotherapy, Vol. 6, No. 3, 1994, p. 204-210.

Research output: Contribution to journalArticle

Bacci, G, Ferrari, S, Sangiorgi, L, Picci, P, Casadei, R, Orlandi, M, Iantorno, D, Battistini, A & Zanone, A 1994, 'Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities', Journal of Chemotherapy, vol. 6, no. 3, pp. 204-210.
Bacci, G. ; Ferrari, S. ; Sangiorgi, L. ; Picci, P. ; Casadei, R. ; Orlandi, M. ; Iantorno, D. ; Battistini, A. ; Zanone, A. / Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. In: Journal of Chemotherapy. 1994 ; Vol. 6, No. 3. pp. 204-210.
@article{f6c52e562ecc4648a532a6ec009d633c,
title = "Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities",
abstract = "Six hundred and fifty-six patients with osteosarcoma of the extremities (107 metastatic and 549 with localized disease) were followed from 2.5 to 20 years (average: 10 years) to evaluate whether their pretreatment serum lactate dehydrogenase (LDH) enzyme levels had a clinical value in predicting the course of the disease. The percentage of patients who had an elevated serum LDH at the time of diagnosis was significantly higher in those patients with metastatic disease than those who had localized disease (64{\%} versus 33{\%}, p <0.0001). For those who presented with localized disease and had an increased serum LDH level, far more ultimately developed a relapse of disease (60{\%} versus 38{\%}, p <0.0001) than those patients with a normal pre-treatment value. The prognostic significance of the serum LDH was more pronounced for the 247 patients treated with adjuvant chemotherapy (relapse rate of 72{\%} versus 48{\%}: p <0.0002) than the 271 patients treated with neoadjuvant chemotherapy (relapse rate: 46{\%} versus 28{\%}, p <0.005). Following treatment, serum LDH levels almost uniformly returned to normal and no correlation between postoperative levels and relapse of disease could be identified. We have demonstrated that in patients with osteosarcoma of the extremities, pretreatment serum LDH levels have a definite prognostic value which should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.",
keywords = "lactate dehydrogenase, osteosarcoma, serum LDH",
author = "G. Bacci and S. Ferrari and L. Sangiorgi and P. Picci and R. Casadei and M. Orlandi and D. Iantorno and A. Battistini and A. Zanone",
year = "1994",
language = "English",
volume = "6",
pages = "204--210",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "3",

}

TY - JOUR

T1 - Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities

AU - Bacci, G.

AU - Ferrari, S.

AU - Sangiorgi, L.

AU - Picci, P.

AU - Casadei, R.

AU - Orlandi, M.

AU - Iantorno, D.

AU - Battistini, A.

AU - Zanone, A.

PY - 1994

Y1 - 1994

N2 - Six hundred and fifty-six patients with osteosarcoma of the extremities (107 metastatic and 549 with localized disease) were followed from 2.5 to 20 years (average: 10 years) to evaluate whether their pretreatment serum lactate dehydrogenase (LDH) enzyme levels had a clinical value in predicting the course of the disease. The percentage of patients who had an elevated serum LDH at the time of diagnosis was significantly higher in those patients with metastatic disease than those who had localized disease (64% versus 33%, p <0.0001). For those who presented with localized disease and had an increased serum LDH level, far more ultimately developed a relapse of disease (60% versus 38%, p <0.0001) than those patients with a normal pre-treatment value. The prognostic significance of the serum LDH was more pronounced for the 247 patients treated with adjuvant chemotherapy (relapse rate of 72% versus 48%: p <0.0002) than the 271 patients treated with neoadjuvant chemotherapy (relapse rate: 46% versus 28%, p <0.005). Following treatment, serum LDH levels almost uniformly returned to normal and no correlation between postoperative levels and relapse of disease could be identified. We have demonstrated that in patients with osteosarcoma of the extremities, pretreatment serum LDH levels have a definite prognostic value which should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.

AB - Six hundred and fifty-six patients with osteosarcoma of the extremities (107 metastatic and 549 with localized disease) were followed from 2.5 to 20 years (average: 10 years) to evaluate whether their pretreatment serum lactate dehydrogenase (LDH) enzyme levels had a clinical value in predicting the course of the disease. The percentage of patients who had an elevated serum LDH at the time of diagnosis was significantly higher in those patients with metastatic disease than those who had localized disease (64% versus 33%, p <0.0001). For those who presented with localized disease and had an increased serum LDH level, far more ultimately developed a relapse of disease (60% versus 38%, p <0.0001) than those patients with a normal pre-treatment value. The prognostic significance of the serum LDH was more pronounced for the 247 patients treated with adjuvant chemotherapy (relapse rate of 72% versus 48%: p <0.0002) than the 271 patients treated with neoadjuvant chemotherapy (relapse rate: 46% versus 28%, p <0.005). Following treatment, serum LDH levels almost uniformly returned to normal and no correlation between postoperative levels and relapse of disease could be identified. We have demonstrated that in patients with osteosarcoma of the extremities, pretreatment serum LDH levels have a definite prognostic value which should be considered when comparing the results achieved with different therapeutic protocols and in planning new randomized clinical trials.

KW - lactate dehydrogenase

KW - osteosarcoma

KW - serum LDH

UR - http://www.scopus.com/inward/record.url?scp=0028101323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028101323&partnerID=8YFLogxK

M3 - Article

C2 - 7983504

AN - SCOPUS:0028101323

VL - 6

SP - 204

EP - 210

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 3

ER -